Use with extreme caution in patients on monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, and drugs which prolong the QT interval (due to potentiation of effect of adrenergic agents on the cardiovascular system)
Paradoxical Brochospasm (see Obstructive Lung Disease, [[Obstructive Lung Disease]]): although uncommon, this may occur with all β2-adrenergic receptor agonists
Other Adverse Effects
Increased Risk of Death in Asthma: class effect for all β2-adrenergic receptor agonists
Pain: occurs in 8% of cases (vs 5% of placebo-treated cases)